MLYS,ESPR Stock Price and Quote

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Peers: CGON KYMR NUVL INCY RYTM APGE KRYS AXSM BMRN NBIX

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT DFAS

Index	RUT
Market Cap	2.38B
Enterprise Value	1.73B
Income	-151.78M
Sales	0.00M
Book/sh	7.74
Cash/sh	7.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Feb 10, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.49
P/C	3.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	44.33
Current Ratio	44.33
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.06
EPS next Y	-2.10
EPS next Q	-0.55
EPS this Y	-0.87%
EPS next Y	9.25%
EPS next 5Y	20.15%
EPS past 3/5Y	-46.34% -101.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	44.87%
Sales Y/Y TTM	-
EPS Q/Q	40.19%
Sales Q/Q	-
Earnings	May 06 AMC
EPS/Sales Surpr.	0.47% -

Insider Own	26.47%
Insider Trans	-1.43%
Inst Own	82.38%
Inst Trans	1.62%
ROA	-30.12%
ROE	-30.98%
ROIC	-23.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.50%
SMA50	-1.07%
SMA200	-17.68%
Trades

Shs Outstand	82.45M
Shs Float	64.82M
Short Float	13.42%
Short Ratio	5.53
Short Interest	8.70M
52W High	47.65 -43.38%
52W Low	12.59 114.30%
Volatility	4.79% 5.65%
ATR (14)	1.46
RSI (14)	54.76
Beta	0.68
Rel Volume	1.29
Avg Volume	1.57M
Volume	2,025,580

Perf Week	5.35%
Perf Month	-14.35%
Perf Quarter	14.76%
Perf Half Y	-27.36%
Perf YTD	-25.65%
Perf Year	99.41%
Perf 3Y	58.24%
Perf 5Y	-
Perf 10Y	-
Recom	1.22
Target Price	49.00
Prev Close	26.88
Price	26.98
Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	TD Cowen	Buy
Jun-11-25	Initiated	Jefferies	Hold	$15
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Jun-14-26 10:00AM	Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) (GlobeNewswire)
Jun-08-26 04:05PM	Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) -5.02% +7.47%
07:00AM	Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) (GlobeNewswire)
Jun-03-26 06:05AM	Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire) -13.14%
06:00AM	Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing (GlobeNewswire)
11:15AM	Loading…
May-30-26 11:15AM	Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-27-26 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-18-26 04:05PM	Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) (GlobeNewswire)
May-06-26 08:30PM	Mineralys Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
04:05PM	Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-26 05:34PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-29-26 04:05PM	Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 (GlobeNewswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +15.23%
Mar-24-26 08:00AM	Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer (GlobeNewswire)
04:05PM	Loading…
Mar-16-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 08:30AM	Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-12-26 11:06PM	Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
04:05PM	Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 04:30PM	Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 (GlobeNewswire)
Feb-26-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-26 07:00PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.45%
Jan-30-26 12:24AM	Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones (Insider Monkey)
Jan-06-26 08:00AM	Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-12-25 11:00AM	Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup (GlobeNewswire)
Dec-05-25 09:55AM	Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet (Zacks)
Nov-26-25 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:02AM	Loading…
Nov-11-25 12:02AM	Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) +5.87%
Nov-10-25 04:05PM	Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.04%
Nov-07-25 06:10PM	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Nov-05-25 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.66%
Nov-03-25 08:00AM	Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-17-25 09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Sep-30-25 12:34PM	Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups (Insider Monkey)
08:00AM	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension (GlobeNewswire)
Sep-29-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-16-25 05:41PM	It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps (Motley Fool)
Sep-09-25 12:00PM	What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? (Zacks) +7.15%
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-05-25 09:00AM	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need (GlobeNewswire) +5.07%
Sep-04-25 04:01PM	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.23%
Sep-03-25 11:13AM	Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak (Insider Monkey)
Sep-02-25 09:33PM	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +86.43%
04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:05PM	Why Mineralys Nearly Doubled On AstraZeneca's Hypertension Results (Investor's Business Daily)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-30-25 10:15AM	AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results (Investor's Business Daily)
Aug-18-25 09:55AM	Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade (Zacks) +5.65%
Aug-13-25 03:12AM	Mineralys Therapeutics Inc (MLYS) Q2 2025 Earnings Call Highlights: Pivotal Trial Success and ... (GuruFocus.com)
Aug-12-25 04:05PM	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 (GlobeNewswire)
Jul-25-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? (Zacks)
Jul-01-25 02:42AM	Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM	Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM	Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM	Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM	Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM	Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-12-25 04:05PM	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
May-05-25 04:05PM	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 (GlobeNewswire) -7.49%
Apr-23-25 05:23PM	Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) (GlobeNewswire)
Mar-29-25 02:30PM	Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) (GlobeNewswire)
Mar-25-25 11:28AM	Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
08:00AM	Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET (GlobeNewswire)
Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)
07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension (GlobeNewswire)
06:30AM	Mineralys shares climb on study data for blood pressure drug (BioPharma Dive)
Mar-07-25 04:01PM	Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET (GlobeNewswire)
Feb-13-25 02:19AM	Q4 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ... (GuruFocus.com)
Feb-12-25 07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.04%
Feb-05-25 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 (GlobeNewswire)
Feb-04-25 08:00AM	Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria (GlobeNewswire)
Jan-09-25 08:29AM	Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials (TipRanks)
Jan-08-25 08:00AM	Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension (GlobeNewswire) -13.71%
Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

PresidentDr. Jon Congleton

M.P.H.Dr. Brian Taylor Slingsby M.D.

CFO & SecretaryMr. Adam Scott Levy

Chief Medical OfficerDr. David M. Rodman M.D.

Chief Legal OfficerMr. Jeffrey A. Munsie J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Congleton Jon	Chief Executive Officer	Jun 30 '26	Sale	26.14	75,000	1,960,601	614,321	Jun 30 06:41 PM
Warren Eric	Chief Commercial Officer	Jun 26 '26	Option Exercise	13.24	104,124	1,378,602	142,524	Jun 30 06:41 PM
Warren Eric	Chief Commercial Officer	Jun 26 '26	Sale	25.90	104,124	2,696,322	38,400	Jun 30 06:41 PM
Congleton Jon	Officer	Jun 30 '26	Proposed Sale	26.14	75,000	1,960,602		Jun 30 04:20 PM
Warren Eric	Officer	Jun 26 '26	Proposed Sale	25.90	104,124	2,696,322		Jun 29 09:05 AM
Rodman David Malcom	Chief Medical Officer	Jun 17 '26	Option Exercise	14.36	4,584	65,818	61,679	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 15 '26	Option Exercise	10.20	3,542	36,128	66,985	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 15 '26	Sale	23.81	9,890	235,487	57,095	Jun 17 09:18 PM
Rodman David Malcom	Chief Medical Officer	Jun 17 '26	Sale	25.00	4,584	114,600	57,095	Jun 17 09:18 PM
Karydas Daphne	Director	Jun 17 '26	Option Exercise	12.02	3,000	36,060	9,200	Jun 17 09:18 PM
Karydas Daphne	Director	Jun 17 '26	Sale	25.00	3,000	75,000	6,200	Jun 17 09:18 PM
Rodman David Malcom	Officer	Jun 17 '26	Proposed Sale	25.00	4,584	114,600		Jun 17 04:20 PM
Karydas Daphne	Officer	Jun 17 '26	Proposed Sale	25.00	3,000	75,000		Jun 17 04:15 PM
Rodman David Malcom	Officer	Jun 15 '26	Proposed Sale	23.81	9,890	235,487		Jun 15 04:58 PM
Rodman David Malcom	Chief Medical Officer	Jun 10 '26	Option Exercise	16.00	2,170	34,720	65,613	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '26	Option Exercise	1.08	6,349	6,857	69,792	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '26	Sale	23.93	6,349	151,901	63,443	Jun 12 06:04 PM
Rodman David Malcom	Chief Medical Officer	Jun 10 '26	Sale	25.00	2,170	54,250	63,443	Jun 12 06:04 PM
Rodman David Malcom	Officer	Jun 12 '26	Proposed Sale	23.93	6,349	151,901		Jun 12 04:17 PM
Rodman David Malcom	Officer	Jun 10 '26	Proposed Sale	25.00	2,170	54,250		Jun 10 04:11 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Option Exercise	15.44	417	6,438	63,860	May 19 07:15 PM
Rodman David Malcom	Chief Medical Officer	May 18 '26	Sale	27.55	417	11,488	63,443	May 19 07:15 PM
Rodman David Malcom	Officer	May 18 '26	Proposed Sale	27.55	417	11,488		May 18 04:10 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Option Exercise	12.39	7,707	95,484	77,499	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Option Exercise	16.00	2,171	34,736	71,963	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Option Exercise	1.08	6,348	6,856	76,140	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 13 '26	Sale	28.58	14,056	401,789	63,443	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 12 '26	Sale	29.36	6,348	186,348	69,792	May 13 09:42 PM
Rodman David Malcom	Chief Medical Officer	May 11 '26	Sale	29.71	2,171	64,500	69,792	May 13 09:42 PM
Rodman David Malcom	Officer	May 13 '26	Proposed Sale	28.58	14,056	401,790		May 13 04:11 PM
Rodman David Malcom	Officer	May 12 '26	Proposed Sale	29.36	6,348	186,348		May 12 05:05 PM
Rodman David Malcom	Officer	May 11 '26	Proposed Sale	29.71	2,171	64,500		May 11 04:27 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Option Exercise	15.44	416	6,423	70,208	Apr 21 06:59 PM
Rodman David Malcom	Chief Medical Officer	Apr 17 '26	Sale	31.33	416	13,033	69,792	Apr 21 06:59 PM
Rodman David Malcom	Officer	Apr 17 '26	Proposed Sale	31.33	416	13,033		Apr 17 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Option Exercise	7.28	14,058	102,365	90,198	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 13 '26	Sale	26.54	14,058	373,087	76,140	Apr 15 09:45 PM
Rodman David Malcom	Chief Medical Officer	Apr 15 '26	Sale	27.66	6,348	175,586	69,792	Apr 15 09:45 PM
Congleton Jon	Chief Executive Officer	Apr 13 '26	Sale	26.83	15,730	421,979	689,321	Apr 15 09:45 PM
Rodman David Malcom	Officer	Apr 15 '26	Proposed Sale	27.66	6,348	175,586		Apr 15 04:21 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Option Exercise	16.00	2,170	34,720	78,310	Apr 13 09:13 PM
Rodman David Malcom	Chief Medical Officer	Apr 09 '26	Sale	27.38	2,170	59,415	76,140	Apr 13 09:13 PM
Congleton Jon	Officer	Apr 13 '26	Proposed Sale	26.83	15,730	421,980		Apr 13 04:22 PM
Rodman David Malcom	Officer	Apr 13 '26	Proposed Sale	26.54	14,058	373,087		Apr 13 04:18 PM
Rodman David Malcom	Officer	Apr 09 '26	Proposed Sale	27.38	2,170	59,415		Apr 09 04:24 PM
Congleton Jon	Chief Executive Officer	Mar 31 '26	Sale	26.27	75,000	1,970,522	705,051	Apr 02 06:54 PM
Karydas Daphne	Director	Mar 31 '26	Option Exercise	12.02	3,000	36,060	9,200	Apr 02 06:53 PM
Karydas Daphne	Director	Mar 31 '26	Sale	25.00	3,000	75,000	6,200	Apr 02 06:53 PM
Karydas Daphne	Officer	Mar 31 '26	Proposed Sale	25.00	3,000	75,000		Mar 31 04:18 PM
Congleton Jon	Officer	Mar 31 '26	Proposed Sale	26.27	75,000	1,970,521		Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '26	Buy	23.67	310,700	7,354,269	5,767,221	Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 30 '26	Buy	24.16	58,300	1,408,528	5,825,521	Mar 31 04:15 PM
Rodman David Malcom	Officer	Mar 17 '26	Proposed Sale	25.65	417	10,696		Mar 17 05:04 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Option Exercise	15.44	417	6,438	76,557	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Sale	25.65	417	10,696	76,140	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Option Exercise	12.39	7,709	95,508	90,198	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Option Exercise	1.08	6,348	6,856	88,837	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Sale	26.26	14,058	369,225	76,140	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Sale	27.37	6,348	173,748	82,489	Mar 16 05:20 PM
Rodman David Malcom	Officer	Mar 13 '26	Proposed Sale	26.26	14,058	369,225		Mar 13 04:50 PM
Rodman David Malcom	Officer	Mar 12 '26	Proposed Sale	27.37	6,348	173,748		Mar 12 04:13 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Option Exercise	16.00	2,171	34,736	84,660	Mar 10 05:48 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Sale	26.84	2,171	58,270	82,489	Mar 10 05:48 PM
Rodman David Malcom	Officer	Mar 09 '26	Proposed Sale	26.84	2,171	58,270		Mar 09 05:15 PM
Rodman David Malcom	Chief Medical Officer	Feb 17 '26	Option Exercise	15.44	417	6,438	44,506	Feb 17 06:56 PM
Rodman David Malcom	Chief Medical Officer	Feb 17 '26	Sale	27.59	417	11,505	44,089	Feb 17 06:56 PM
Rodman David Malcom	Officer	Feb 17 '26	Proposed Sale	27.59	417	11,505		Feb 17 04:05 PM
Rodman David Malcom	Chief Medical Officer	Feb 13 '26	Option Exercise	12.39	7,707	95,484	54,603	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '26	Option Exercise	1.08	6,349	6,857	56,786	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 13 '26	Sale	27.44	14,055	385,732	44,089	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '26	Sale	28.99	6,349	184,077	50,437	Feb 13 07:25 PM
Rodman David Malcom	Officer	Feb 13 '26	Proposed Sale	27.44	14,055	385,732		Feb 13 04:07 PM
Rodman David Malcom	Officer	Feb 12 '26	Proposed Sale	28.99	6,349	184,077		Feb 12 04:34 PM
Rodman David Malcom	Chief Medical Officer	Feb 09 '26	Option Exercise	16.00	2,171	34,736	52,608	Feb 11 06:58 PM
Rodman David Malcom	Chief Medical Officer	Feb 09 '26	Sale	30.21	2,171	65,586	50,437	Feb 11 06:58 PM
Rodman David Malcom	Officer	Feb 09 '26	Proposed Sale	30.21	2,171	65,586		Feb 09 04:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 20 '26	Option Exercise	15.44	416	6,423	50,853	Jan 20 08:33 PM
Rodman David Malcom	Chief Medical Officer	Jan 20 '26	Sale	32.10	416	13,354	50,437	Jan 20 08:33 PM
Rodman David Malcom	Officer	Jan 20 '26	Proposed Sale	32.10	416	13,354		Jan 20 04:26 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '26	Option Exercise	12.39	7,709	95,508	69,513	Jan 15 07:07 PM
Rodman David Malcom	Chief Medical Officer	Jan 14 '26	Sale	32.61	11,367	370,645	50,437	Jan 15 07:07 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '26	Sale	32.75	7,709	252,470	61,804	Jan 15 07:07 PM
Rodman David Malcom	Officer	Jan 14 '26	Proposed Sale	32.61	11,367	370,645		Jan 14 04:00 PM
Congleton Jon	Chief Executive Officer	Jan 12 '26	Sale	32.62	16,236	529,640	639,151	Jan 13 08:43 PM
Levy Adam Scott	CFO and Secretary	Jan 12 '26	Sale	32.14	10,758	345,723	8,638	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 09 '26	Option Exercise	16.00	2,170	34,720	63,974	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '26	Option Exercise	1.08	6,348	6,856	68,152	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '26	Sale	32.32	6,348	205,143	61,804	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 09 '26	Sale	33.27	2,170	72,196	61,804	Jan 13 08:43 PM
Rodman David Malcom	Officer	Jan 13 '26	Proposed Sale	32.75	7,709	252,470		Jan 13 04:10 PM
Rodman David Malcom	Officer	Jan 12 '26	Proposed Sale	32.32	6,348	205,143		Jan 12 04:24 PM
Levy Adam Scott	Officer	Jan 12 '26	Proposed Sale	32.14	10,758	345,723		Jan 12 04:23 PM
Congleton Jon	Officer	Jan 12 '26	Proposed Sale	32.62	16,236	529,640		Jan 12 04:23 PM
Rodman David Malcom	Officer	Jan 09 '26	Proposed Sale	33.27	2,170	72,196		Jan 09 04:23 PM
Rodman David Malcom	Chief Medical Officer	Jan 05 '26	Option Exercise	12.26	185,331	2,272,023	254,519	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 02 '26	Option Exercise	12.31	67,390	829,667	139,225	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 05 '26	Sale	35.02	192,715	6,749,109	61,804	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 02 '26	Sale	35.87	70,037	2,511,919	69,188	Jan 06 07:20 PM
Rodman David Malcom	Officer	Jan 02 '26	Proposed Sale	35.71	262,752	9,382,874		Jan 02 05:18 PM
Congleton Jon	Chief Executive Officer	Nov 21 '25	Option Exercise	0.54	24,082	13,004	655,387	Nov 24 05:07 PM

ESPR Esperion Therapeutics Inc daily Stock Chart

Peers: SUPN ALKS PRGO BHC AMRX INDV LNTH TEVA VTRS HRMY

| Held by: VTI IWM FESM VXF XPH IWN VTWO IWO IWC VHT

Index	RUT
Market Cap	814.31M
Enterprise Value	1.20B
Income	-7.42M
Sales	418.24M
Book/sh	-1.20
Cash/sh	0.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	294
IPO	Jun 26, 2013

P/E	-
Forward P/E	11.63
PEG	-
P/S	1.95
P/B	-
P/C	5.21
P/FCF	-
EV/EBITDA	15.84
EV/Sales	2.87
Quick Ratio	1.18
Current Ratio	1.53
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.10
EPS next Y	0.27
EPS next Q	-0.00
EPS this Y	63.64%
EPS next Y	779.17%
EPS next 5Y	-
EPS past 3/5Y	68.58% 53.87%
Sales past 3/5Y	74.80% 12.12%
EPS Y/Y TTM	92.51%
Sales Y/Y TTM	61.13%
EPS Q/Q	51.43%
Sales Q/Q	23.25%
Earnings	May 08 BMO
EPS/Sales Surpr.	-169.54% -5.23%

Insider Own	6.08%
Insider Trans	-0.73%
Inst Own	72.03%
Inst Trans	9.26%
ROA	-1.89%
ROE	-
ROIC	-4.84%
Gross Margin	68.38%
Oper. Margin	18.12%
Profit Margin	-1.77%
SMA20	0.32%
SMA50	8.11%
SMA200	3.98%
Trades

Shs Outstand	257.40M
Shs Float	242.03M
Short Float	8.56%
Short Ratio	1.58
Short Interest	20.72M
52W High	4.18 -24.31%
52W Low	0.95 232.98%
Volatility	0.64% 0.49%
ATR (14)	0.03
RSI (14)	64.24
Beta	1.06
Rel Volume	0.37
Avg Volume	13.14M
Volume	4,881,922

Perf Week	0.00%
Perf Month	0.96%
Perf Quarter	20.15%
Perf Half Y	-21.78%
Perf YTD	-14.59%
Perf Year	221.01%
Perf 3Y	127.34%
Perf 5Y	-85.06%
Perf 10Y	-68.02%
Recom	3.14
Target Price	3.19
Prev Close	3.15
Price	3.16
Change	0.32%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-25-25	Initiated	Piper Sandler	Overweight	$9
Dec-18-24	Initiated	Goldman	Neutral	$4
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$8
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform	$2.50
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11

Show Previous Ratings

Jun-18-26 11:29AM	Are GBTG, BGMS, SUNE, ESPR Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-26-26 08:00AM	Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 (GlobeNewswire)
May-14-26 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-26 08:00AM	Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 (GlobeNewswire)
May-04-26 02:53PM	Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders? (PR Newswire)
11:13AM	Loading…
May-01-26 11:13AM	ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal (Quartz) +55.50%
08:28AM	Summits self-inflicted stumble; Esperions take-private deal (BioPharma Dive)
07:00AM	Esperion to be Acquired by ARCHIMED (GlobeNewswire)
Apr-23-26 08:00AM	Esperion to Report First Quarter 2026 Financial Results on May 7 (GlobeNewswire)
Apr-02-26 04:00PM	Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) (GlobeNewswire)
Mar-31-26 08:00AM	Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 08:00AM	Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 (GlobeNewswire)
Mar-17-26 08:00AM	Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session (GlobeNewswire)
Mar-16-26 06:30AM	Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia (GlobeNewswire) +10.25%
Mar-10-26 03:00PM	Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -11.18%
07:10AM	Loading…
07:10AM	Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates (Zacks)
06:14AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-26 08:20AM	MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-04-26 10:36AM	ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
10:00AM	electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
06:11AM	Esperion to acquire Corstasis for cardiovascular franchise expansion (Pharmaceutical Technology)
05:39AM	Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements (Insider Monkey)
Mar-03-26 08:25AM	Esperion Acquires Enbumyst Maker Corstasis (Benzinga) -11.01%
06:00AM	Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) (Business Wire)
Feb-24-26 10:00AM	Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 (GlobeNewswire)
Feb-18-26 08:00AM	Esperion to Participate in The 2026 Citizens Life Sciences Conference (GlobeNewswire)
Feb-17-26 08:00AM	Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 (GlobeNewswire)
Feb-11-26 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:00PM	Loading…
Jan-11-26 06:00PM	Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 08:00AM	Esperion's Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes (GlobeNewswire)
Dec-09-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-25 08:00AM	Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia (GlobeNewswire)
Nov-19-25 08:00AM	Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-18-25 07:00AM	Esperion Partner HLS Therapeutics Announces Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease (GlobeNewswire)
Nov-10-25 08:00AM	Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 (GlobeNewswire) +8.27%
Nov-07-25 11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks) +6.40%
Nov-06-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -14.97%
02:06PM	Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 08:00AM	Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer (GlobeNewswire)
Nov-03-25 08:00AM	Esperion to Participate in Jefferies Global Healthcare Conference - London (GlobeNewswire)
Oct-28-25 08:00AM	Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. (GlobeNewswire)
Oct-27-25 08:00AM	Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire) +7.01%
Oct-23-25 08:00AM	Esperion to Report Third Quarter 2025 Financial Results on November 6 (GlobeNewswire)
Oct-17-25 11:52AM	ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up (Zacks)
Oct-16-25 08:00AM	Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis (GlobeNewswire) +5.16%
Oct-10-25 01:01AM	ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play (MoneyShow)
Oct-09-25 08:57AM	ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering (Zacks)
Oct-07-25 09:29PM	Esperion Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -16.83%
04:01PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks) -5.45%
Oct-03-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 19, 2040 (GlobeNewswire) +13.79%
Sep-24-25 06:40AM	Oritain expands traceability offer to leather (Just Style)
Sep-19-25 08:00AM	Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia (GlobeNewswire)
Aug-29-25 08:00AM	Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias (GlobeNewswire)
Aug-26-25 08:00AM	Esperion to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-22-25 03:11PM	Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock? (Zacks)
Aug-14-25 06:31AM	HLS Therapeutics Announces Q2 2025 Financial Results (PR Newswire) +6.70%
Aug-07-25 05:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.73%
Aug-06-25 11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks) +18.52%
Aug-05-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.72%
06:14AM	Esperion Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-29-25 10:00AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) -7.55%
09:34AM	Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors (Insider Monkey)
Jul-22-25 08:00AM	Esperion to Report Second Quarter 2025 Financial Results on August 5 (GlobeNewswire) +6.09%
Jul-17-25 07:00AM	Whats the Status on Digital Product Passport Implementation? (Sourcing Journal) +10.71%
Jul-08-25 08:00AM	Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +5.41%
Jul-01-25 08:06AM	Esperion Appoints Craig Thompson to Board of Directors (GlobeNewswire)
Jun-05-25 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? (Zacks)
Jun-02-25 08:00AM	Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +8.10%
May-20-25 08:00AM	Esperion to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.19%
May-12-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire)
May-09-25 09:55AM	HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines (Pharmaceutical Technology) -10.60%
08:00AM	Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:32AM	HLS Therapeutics Announces Q1 2025 Financial Results (PR Newswire)
06:30AM	HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada (PR Newswire)
06:30AM	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada (GlobeNewswire)
May-07-25 12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks) -10.72%
03:05AM	Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
May-06-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.10%
06:10AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.80%
Apr-25-25 08:00AM	Esperion to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -7.15%
08:00AM	Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 (GlobeNewswire)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:00AM	Esperion to Report First Quarter 2025 Financial Results on May 6 (GlobeNewswire)
Apr-22-25 09:35AM	Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +9.12%
Apr-21-25 05:32PM	Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -10.32%

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

PresidentMr. Sheldon L. Koenig M.B.A.

Chief Financial OfficerMr. Benjamin Halladay M.B.A.

Chief Commercial OfficerMr. John B. Harlow Jr.

Chief Technical Operations OfficerMr. Glenn P. Brame

Chief Legal & Corporate Affairs OfficerMr. Benjamin O. Looker J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Looker Benjamin	Chief Legal Officer	Jun 17 '26	Sale	3.15	11,824	37,305	667,524	Jun 18 04:06 PM
Koenig Sheldon L.	President and CEO	Jun 17 '26	Sale	3.15	53,588	169,070	2,119,111	Jun 18 04:06 PM
Halladay Benjamin	Chief Financial Officer	Jun 17 '26	Sale	3.15	10,773	33,989	702,829	Jun 18 04:05 PM
Koenig Sheldon L.	Officer	Jun 17 '26	Proposed Sale	3.15	53,588	169,059		Jun 17 03:34 PM
Halladay Benjamin	Officer	Jun 17 '26	Proposed Sale	3.15	10,773	33,986		Jun 17 03:23 PM
Looker Benjamin	Officer	Jun 17 '26	Proposed Sale	3.15	11,824	37,301		Jun 17 03:11 PM
Looker Benjamin	Chief Legal Officer	Mar 17 '26	Sale	2.70	5,708	15,429	679,348	Mar 18 04:13 PM
Koenig Sheldon L.	President and CEO	Mar 17 '26	Sale	2.72	25,578	69,547	2,172,699	Mar 18 04:13 PM
Halladay Benjamin	Chief Financial Officer	Mar 17 '26	Sale	2.71	6,424	17,377	713,602	Mar 18 04:12 PM
Halladay Benjamin	Officer	Mar 17 '26	Proposed Sale	2.70	6,424	17,375		Mar 17 03:19 PM
Looker Benjamin	Officer	Mar 17 '26	Proposed Sale	2.70	5,708	15,428		Mar 17 03:17 PM
Koenig Sheldon L.	Officer	Mar 17 '26	Proposed Sale	2.72	25,578	69,552		Mar 17 03:12 PM
Looker Benjamin	General Counsel	Jan 20 '26	Sale	2.88	1,689	4,868	384,216	Jan 21 05:17 PM
Looker Benjamin	Officer	Jan 20 '26	Proposed Sale	2.88	1,689	4,867		Jan 20 03:14 PM
Koenig Sheldon L.	President and CEO	Dec 17 '25	Sale	3.67	48,244	177,200	1,470,587	Dec 18 04:10 PM
Halladay Benjamin	Chief Financial Officer	Dec 17 '25	Sale	3.67	7,337	26,905	467,525	Dec 18 04:09 PM
Looker Benjamin	General Counsel	Dec 17 '25	Sale	3.67	6,517	23,898	385,905	Dec 18 04:09 PM
Koenig Sheldon L.	Officer	Dec 17 '25	Proposed Sale	3.67	48,244	177,200		Dec 17 03:52 PM
Looker Benjamin	Officer	Dec 17 '25	Proposed Sale	3.67	6,517	23,897		Dec 17 03:26 PM
Halladay Benjamin	Officer	Dec 17 '25	Proposed Sale	3.67	7,337	26,906		Dec 17 03:18 PM
Looker Benjamin	Officer	Oct 17 '25	Proposed Sale	2.62	1,248	3,275		Oct 17 03:13 PM
Looker Benjamin	General Counsel	Sep 17 '25	Sale	2.80	6,267	17,573	393,670	Sep 18 04:06 PM
Koenig Sheldon L.	President and CEO	Sep 17 '25	Sale	2.79	28,427	79,254	1,518,831	Sep 18 04:06 PM
Halladay Benjamin	Chief Financial Officer	Sep 17 '25	Sale	2.81	7,046	19,785	474,862	Sep 18 04:06 PM
Koenig Sheldon L.	Officer	Sep 17 '25	Proposed Sale	2.79	28,427	79,240		Sep 17 03:37 PM
Halladay Benjamin	Officer	Sep 17 '25	Proposed Sale	2.81	7,046	19,789		Sep 17 03:30 PM
Looker Benjamin	Officer	Sep 17 '25	Proposed Sale	2.80	6,267	17,576		Sep 17 03:25 PM
Looker Benjamin	General Counsel	Jul 17 '25	Sale	1.13	1,304	1,470	399,937	Jul 18 04:07 PM
Halladay Benjamin	Chief Financial Officer	Jul 17 '25	Sale	1.11	11	12	474,462	Jul 18 04:05 PM
Looker Benjamin	Officer	Jul 17 '25	Proposed Sale	1.13	1,304	1,469		Jul 17 05:09 PM
Halladay Benjamin	Officer	Jul 17 '25	Proposed Sale	1.12	11	12		Jul 17 03:39 PM

$100 Off Your First Year Get Elite For Just $199.50

MLYS

Mineralys Therapeutics Inc

ESPR

Esperion Therapeutics Inc

Upgrade your Finviz experience